Lunsumio Mosunetuzumab Follicular Lymphoma Bispecific Review 2026
Author: Critical Kare PharmaLymphoma & Bispecific Desk
On October 17, 2026, international hematology congresses reaffirmed Lunsumio® (Mosunetuzumab-axgb 1 mg/mL and 30 mg/30 mL solution for infusion) by Genentech / Roche as a landmark CD20xCD3 T-cell engager for relapsed/refractory follicular lymphoma.
As an off-the-shelf, fixed-duration immunotherapy administered in the outpatient setting without requiring continuous therapy, Lunsumio achieves high, durable complete remissions in patients with follicular lymphoma who have received two or more lines of systemic therapy.
Through Critical Kare Pharma, certified genuine packs of Lunsumio Mosunetuzumab Infusion Vials are supplied directly to hematology clinics under validated 2°C–8°C cold-chain transport.
The GO29781 Landmark Trial Benchmarks
- High Complete Response Rate: 80% overall response rate with a 60% complete remission rate in heavily pretreated follicular lymphoma.
- Durable Remissions: Median duration of response exceeded 22.8 months with fixed 8-cycle duration for complete responders.
- Step-Up Priming Schedule: Administered with step-up dosing in Cycle 1 (1 mg on Day 1, 2 mg on Day 8, 60 mg on Day 15) to minimize CRS incidence.
Global Sourcing via Critical Kare Pharma
Supplied under US FDA Personal Import, UK Named-Patient Import, and Latin American health permits with end-to-end digital temperature monitoring.
